BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Styczynski J. Who Is the Patient at Risk of CMV Recurrence: A Review of the Current Scientific Evidence with a Focus on Hematopoietic Cell Transplantation. Infect Dis Ther 2018;7:1-16. [PMID: 29204910 DOI: 10.1007/s40121-017-0180-z] [Cited by in Crossref: 72] [Cited by in F6Publishing: 79] [Article Influence: 14.4] [Reference Citation Analysis]
Number Citing Articles
1 Ai Y, Wu C, Zhang M, Jaijyan DK, Liu T, Zan L, Li N, Yu W, Wang Y, Yuan X, Li C, Zheng W, Zhu H, Liao H. Neutralization Epitopes in Trimer and Pentamer Complexes Recognized by Potent Cytomegalovirus-Neutralizing Human Monoclonal Antibodies. Microbiol Spectr 2022. [DOI: 10.1128/spectrum.01393-22] [Reference Citation Analysis]
2 Yang T, Song X, Zhao Y, Ye B, Luo Y, Xiao H, Chen Y, Fu H, Yu J, Liu L, Lai X, Ye Y, Lan J, Huang H, Shi J. Outcome after allogeneic hematopoietic stem cell transplantation following Venetoclax-based therapy among AML and MDS patients. Ann Hematol 2022. [DOI: 10.1007/s00277-022-04983-9] [Reference Citation Analysis]
3 Cui J, Zhao K, Sun Y, Wen R, Zhang X, Li X, Long B. Diagnosis and treatment for the early stage of cytomegalovirus infection during hematopoietic stem cell transplantation. Front Immunol 2022;13:971156. [DOI: 10.3389/fimmu.2022.971156] [Reference Citation Analysis]
4 del Rosal T, Quintana-ortega C, Deyá-martinez A, Soler-palacín P, Goycochea-valdivia WA, Salmón N, Pérez-martínez A, Alsina L, Martín-nalda A, Alonso L, Neth O, Bravo-gallego LY, Gonzalez-granado LI, Mendez-echevarria A. Impact of cytomegalovirus infection prior to hematopoietic stem cell transplantation in children with inborn errors of immunity. Eur J Pediatr. [DOI: 10.1007/s00431-022-04614-5] [Reference Citation Analysis]
5 Fowler K, Mucha J, Neumann M, Lewandowski W, Kaczanowska M, Grys M, Schmidt E, Natenshon A, Talarico C, Buck PO, Diaz-Decaro J. A systematic literature review of the global seroprevalence of cytomegalovirus: possible implications for treatment, screening, and vaccine development. BMC Public Health 2022;22:1659. [PMID: 36050659 DOI: 10.1186/s12889-022-13971-7] [Reference Citation Analysis]
6 Márquez-algaba E, Iacoboni G, Pernas B, Esperalba J, Arcos IL, Navarro V, Monforte A, Beas F, Albasanz-puig A, Carpio C, Barba P, Ruiz-camps I. Impact of Cytomegalovirus Replication in Patients with Aggressive B-Cell Lymphoma Treated with CAR T-Cell Therapy. Transplantation and Cellular Therapy 2022. [DOI: 10.1016/j.jtct.2022.09.007] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Zdziarski P, Gamian A. High Monocyte Count Associated with Human Cytomegalovirus Replication In Vivo and Glucocorticoid Therapy May Be a Hallmark of Disease. IJMS 2022;23:9595. [DOI: 10.3390/ijms23179595] [Reference Citation Analysis]
8 Liu Y, Liu Y, Chen X, Jia Y. . IDR 2022;Volume 15:5011-21. [DOI: 10.2147/idr.s376763] [Reference Citation Analysis]
9 Khawaja F, Spallone A, Kotton CN, Chemaly RF. Cytomegalovirus infection in transplant recipients: Newly approved additions to our armamentarium. Clin Microbiol Infect 2022:S1198-743X(22)00348-2. [PMID: 35843567 DOI: 10.1016/j.cmi.2022.07.001] [Reference Citation Analysis]
10 Bankur MN, Keeling A, Adil Shah KM, Avenoso D. CMV Colitis: A Rare Complication of Azacitidine and Venetoclax Chemotherapy. Hematology Reports 2022;14:213-21. [DOI: 10.3390/hematolrep14030029] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Dmitrova AA, Drokov MY, Tupoleva TA, Savchenko VG. Cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation: clinical significance and definitions. Transplantologiâ (Mosk ) 2022;14:210-225. [DOI: 10.23873/2074-0506-2022-14-2-210-225] [Reference Citation Analysis]
12 Aristizabal AM, Perez P, Patiño Niño JA, Franco A, Tarapues EM, Beltran E, Medina D. Risk factors and incidence of cytomegalovirus viremia and disease in pediatric patients with allogeneic hematopoietic stem cell transplantation: An 8-year single-center experience in Latin America. Pediatr Transplant 2022;:e14324. [PMID: 35647735 DOI: 10.1111/petr.14324] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Cheng WY, Avery RK, Thompson-Leduc P, Cheung HC, Bo T, Duh MS, Hirji I. Evaluation of treatment patterns, healthcare resource utilization, and costs among patients receiving treatment for cytomegalovirus following allogeneic hematopoietic cell or solid organ transplantation. J Med Econ 2022;:1-39. [PMID: 35240904 DOI: 10.1080/13696998.2022.2046388] [Reference Citation Analysis]
14 Otto WR, Green A. Antiviral Therapeutics in Pediatric Transplant Recipients. Infectious Disease Clinics of North America 2022;36:125-46. [DOI: 10.1016/j.idc.2021.11.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Yu HC, Liu WD, Kuo PH, Lin CC, Wu UI. Cutaneous presentation of disseminated cytomegalovirus infection in a non-transplant patient with hematological malignancy: A case report. Medicine (Baltimore) 2022;101:e28721. [PMID: 35119018 DOI: 10.1097/MD.0000000000028721] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Ivana T, Robert P, Pavel S, Lenka T, Irena K. Cytomegalovirus and other herpesviruses after hematopoietic cell and solid organ transplantation: From antiviral drugs to virus-specific T cells. Transpl Immunol 2022;:101539. [PMID: 35051589 DOI: 10.1016/j.trim.2022.101539] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
17 Schulze Lammers FC, Bonifacius A, Tischer-Zimmermann S, Goudeva L, Martens J, Lepenies B, von Karpowitz M, Einecke G, Beutel G, Skripuletz T, Blasczyk R, Beier R, Maecker-Kolhoff B, Eiz-Vesper B. Antiviral T-Cell Frequencies in a Healthy Population: Reference Values for Evaluating Antiviral Immune Cell Profiles in Immunocompromised Patients. J Clin Immunol 2022. [PMID: 34989946 DOI: 10.1007/s10875-021-01205-1] [Reference Citation Analysis]
18 Camacho-bydume C, Mauguen A, Rodriguez-sanchez MI, Klein E, Kernan NA, Prockop S, Boelens JJ, Papanicolaou GA, Cancio M. Time to initiation of pre-emptive therapy for cytomegalovirus impacts overall survival in pediatric hematopoietic stem cell transplant recipients. Cytotherapy 2022. [DOI: 10.1016/j.jcyt.2021.10.002] [Reference Citation Analysis]
19 Namdari H, Hosseini M, Yazdanifar M, Farajifard H, Parvizpour F, Karamigolbaghi M, Hamidieh AA, Rezaei F. Protective and pathological roles of regulatory immune cells in human cytomegalovirus infection following hematopoietic stem cell transplantation. Rev Med Virol 2021;:e2319. [PMID: 34914147 DOI: 10.1002/rmv.2319] [Reference Citation Analysis]
20 Groves IJ, Jackson SE, Poole EL, Nachshon A, Rozman B, Schwartz M, Prinjha RK, Tough DF, Sinclair JH, Wills MR. Bromodomain proteins regulate human cytomegalovirus latency and reactivation allowing epigenetic therapeutic intervention. Proc Natl Acad Sci U S A 2021;118:e2023025118. [PMID: 33619107 DOI: 10.1073/pnas.2023025118] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 11.0] [Reference Citation Analysis]
21 Wieland A, Ahmed R. Immunological lessons from CD28 deficiency in humans. Cell 2021;184:3595-7. [PMID: 34242561 DOI: 10.1016/j.cell.2021.06.014] [Reference Citation Analysis]
22 Mandura RA, Talat K, Jastaniah W. Unilateral Cytomegalovirus Retinitis in a Child With Acute Lymphoblastic Leukemia While on Maintenance Chemotherapy. Cureus 2021;13:e15246. [PMID: 34188986 DOI: 10.7759/cureus.15246] [Reference Citation Analysis]
23 Kaito S, Nakajima Y, Hara K, Toya T, Nishida T, Uchida N, Mukae J, Fukuda T, Ozawa Y, Tanaka M, Ikegame K, Katayama Y, Kuriyama T, Kanda J, Atsuta Y, Ogata M, Taguchi A, Ohashi K. Heterogeneous impact of cytomegalovirus reactivation on nonrelapse mortality in hematopoietic stem cell transplantation. Blood Adv 2020;4:1051-61. [PMID: 32191806 DOI: 10.1182/bloodadvances.2019000814] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
24 Lee BJ, Min CK, Hancock M, Streblow DN, Caposio P, Goodrum FD, Yurochko AD. Human Cytomegalovirus Host Interactions: EGFR and Host Cell Signaling Is a Point of Convergence Between Viral Infection and Functional Changes in Infected Cells. Front Microbiol 2021;12:660901. [PMID: 34025614 DOI: 10.3389/fmicb.2021.660901] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
25 García-Ríos E, Nuévalos M, Mancebo FJ, Pérez-Romero P. Is It Feasible to Use CMV-Specific T-Cell Adoptive Transfer as Treatment Against Infection in SOT Recipients? Front Immunol 2021;12:657144. [PMID: 33968058 DOI: 10.3389/fimmu.2021.657144] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
26 Golan Y, Tang Y, Mt-Isa S, Wan H, Teal V, Badshah C, Dadwal S. Impact of Letermovir Use for Cytomegalovirus Prophylaxis on Re-Hospitalization Following Allogeneic Hematopoietic Stem Cell Transplantation: An Analysis of a Phase III Randomized Clinical Trial. Pharmacoecon Open 2021;5:469-73. [PMID: 33871830 DOI: 10.1007/s41669-021-00264-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
27 Vezzani G, Amendola D, Yu D, Chandramouli S, Frigimelica E, Maione D, Merola M. The Human Cytomegalovirus UL116 Glycoprotein Is a Chaperone to Control gH-Based Complexes Levels on Virions. Front Microbiol 2021;12:630121. [PMID: 33889136 DOI: 10.3389/fmicb.2021.630121] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
28 Yang SL, Lin TW, Lin HC, Wang HY, Chang PY, Wang PN, Yang S, Lu JJ. Molecular Epidemiology of Cytomegalovirus UL97 and UL54 variants in Taiwan. J Microbiol Immunol Infect 2021;54:971-8. [PMID: 33632621 DOI: 10.1016/j.jmii.2021.01.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Zhou X, Jin N, Chen B. Human cytomegalovirus infection: A considerable issue following allogeneic hematopoietic stem cell transplantation. Oncol Lett 2021;21:318. [PMID: 33692850 DOI: 10.3892/ol.2021.12579] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
30 Baldo F, Suárez NM, Davison AJ, Zanon D, Barbi E, Maximova N. Post-HSCT graft failure due to refractory human cytomegalovirus successfully treated with haploidentical donor-derived immunoglobulins and stem cell graft infusion: A case report. Antiviral Res 2021;188:105024. [PMID: 33577809 DOI: 10.1016/j.antiviral.2021.105024] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Antonova TV, Pobegalova OE, Nozhkin MS, Romanova MA, Gorchakova OV. The impact of viral infections on the results of hemopoietic stem cell transplantation in patients with hematologic malignancies. test 2021;12:85-92. [DOI: 10.22625/2072-6732-2020-12-5-85-92] [Reference Citation Analysis]
32 Gudiol C, Lewis RE, Strati P, Kontoyiannis DP. Chimeric antigen receptor T-cell therapy for the treatment of lymphoid malignancies: is there an excess risk for infection? Lancet Haematol 2021;8:e216-28. [PMID: 33460558 DOI: 10.1016/S2352-3026(20)30376-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 18.0] [Reference Citation Analysis]
33 Jerry Teng CL, Wang PN, Chen YC, Ko BS. Cytomegalovirus management after allogeneic hematopoietic stem cell transplantation: A mini-review. J Microbiol Immunol Infect 2021;54:341-8. [PMID: 33514495 DOI: 10.1016/j.jmii.2021.01.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
34 Zhao XY, Pei XY, Chang YJ, Yu XX, Xu LP, Wang Y, Zhang XH, Liu KY, Huang XJ. First-line Therapy With Donor-derived Human Cytomegalovirus (HCMV)-specific T Cells Reduces Persistent HCMV Infection by Promoting Antiviral Immunity After Allogenic Stem Cell Transplantation. Clin Infect Dis. 2020;70:1429-1437. [PMID: 31067570 DOI: 10.1093/cid/ciz368] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 20.0] [Reference Citation Analysis]
35 Styczynski J. Management of Herpesvirus Infections in Hematopoietic Cell Transplant Recipients. Transplantology 2021;2:8-21. [DOI: 10.3390/transplantology2010002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
36 Camargo JF. Cytomegalovirus in Hematopoietic Stem Cell Transplant Recipients: Prevention, Diagnosis, and Treatment. Emerging Transplant Infections 2021. [DOI: 10.1007/978-3-030-25869-6_25] [Reference Citation Analysis]
37 Danziger-isakov LA, Sharma T. Cytomegalovirus. Pediatric Transplant and Oncology Infectious Diseases 2021. [DOI: 10.1016/b978-0-323-64198-2.00026-9] [Reference Citation Analysis]
38 Mardani M, Abolghasemi S, Shabani S, Tavakoli F, Saeedi A, Parkhideh S, Hajifathali A. The association of conditioning regimen with cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation. Iran J Microbiol 2020;12:636-43. [PMID: 33613920 DOI: 10.18502/ijm.v12i6.5040] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
39 Styczyński J, Tridello G, Xhaard A, Medinger M, Mielke S, Taskinen M, Blijlevens N, Rodriguez MAB, Solano C, Nikolousis E, Biffi A, Groll AH, Junghanss C, Tsirigotis P, Lioure B, Šrámek J, Holler E, Galaverna F, Fagioli F, Knelange N, Wendel L, Gil L, de la Camara R, Mikulska M, Ljungman P. Use of letermovir in off-label indications: Infectious Diseases Working Party of European Society of Blood and Marrow Transplantation retrospective study. Bone Marrow Transplant 2021;56:1171-9. [PMID: 33288863 DOI: 10.1038/s41409-020-01166-w] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
40 Vezzani G, Amendola D, Yu D, Chandramuli S, Frigimelica E, Maione D, Merola M. The human cytomegalovirus UL116 glycoprotein is a chaperone to control gH-based complexes levels on virions.. [DOI: 10.1101/2020.11.18.387126] [Reference Citation Analysis]
41 Forlanini F, Dara J, Dvorak CC, Cowan MJ, Puck JM, Dorsey MJ. Unknown cytomegalovirus serostatus in primary immunodeficiency disorders: A new category of transplant recipients. Transpl Infect Dis 2021;23:e13504. [PMID: 33169931 DOI: 10.1111/tid.13504] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
42 Шепетько М, Губанова Т, Миланович Н, Искров И, Лендина И, Стома И. Herpesvirus Infections in Adult Patients in Transplantation of Hematopoietic Stem Cells: Results of a Clinical Study. Гематология. Трансфузиология. Восточная Европа 2020. [DOI: 10.34883/pi.2020.6.3.019] [Reference Citation Analysis]
43 Malagola M, Pollara C, Polverelli N, Zollner T, Bettoni D, Gandolfi L, Gramegna D, Morello E, Turra A, Corbellini S, Signorini L, Moioli G, Bernardi S, Zanaglio C, Farina M, Testa TE, Caruso A, Russo D. Advances in CMV Management: A Single Center Real-Life Experience. Front Cell Dev Biol 2020;8:534268. [PMID: 33195184 DOI: 10.3389/fcell.2020.534268] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
44 Alsumali A, Chemaly RF, Graham J, Jiang Y, Merchant S, Miles L, Schelfhout J, Yang J, Tang Y. Cost-effectiveness analysis of cytomegalovirus prophylaxis in allogeneic hematopoietic cell transplant recipients from a US payer perspective. J Med Virol 2021;93:3786-94. [PMID: 32844453 DOI: 10.1002/jmv.26462] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
45 O'Reilly RJ, Prockop S, Hasan A, Doubrovina E. Therapeutic advantages provided by banked virus-specific T-cells of defined HLA-restriction. Bone Marrow Transplant 2019;54:759-64. [PMID: 31431697 DOI: 10.1038/s41409-019-0614-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
46 Boccard M, Albert-Vega C, Mouton W, Durieu I, Brengel-Pesce K, Venet F, Trouillet-Assant S, Ader F. [Functional immunoassays in the setting of infectious risk and immunosuppressive therapy of non-HIV immunocompromised patients]. Rev Med Interne 2020;41:545-51. [PMID: 32624260 DOI: 10.1016/j.revmed.2020.04.008] [Reference Citation Analysis]
47 Rozhnova G, E Kretzschmar M, van der Klis F, van Baarle D, Korndewal M, C Vossen A, van Boven M. Short- and long-term impact of vaccination against cytomegalovirus: a modeling study. BMC Med 2020;18:174. [PMID: 32611419 DOI: 10.1186/s12916-020-01629-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
48 Ye L, Wang J, Teque F, Xie F, Tan Y, Kan YW, Levy JA. Generation of HIV-1-infected patients' gene-edited induced pluripotent stem cells using feeder-free culture conditions. AIDS 2020;34:1127-39. [PMID: 32501846 DOI: 10.1097/QAD.0000000000002535] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
49 Cox M, Adetifa JU, Noho-Konteh F, Njie-Jobe J, Sanyang LC, Drammeh A, Plebanski M, Whittle HC, Rowland-Jones SL, Robertson I, Flanagan KL. Limited Impact of Human Cytomegalovirus Infection in African Infants on Vaccine-Specific Responses Following Diphtheria-Tetanus-Pertussis and Measles Vaccination. Front Immunol 2020;11:1083. [PMID: 32582177 DOI: 10.3389/fimmu.2020.01083] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
50 Yang R, Zhang R, Zhang Y, Huang Y, Liang H, Gui G, Gong S, Wang H, Xu M, Fan J. Risk Factors Analysis for Human Cytomegalovirus Viremia in Donor+/Recipient+ Hematopoietic Stem Cell Transplantation. Lab Med 2020;51:74-9. [PMID: 31150544 DOI: 10.1093/labmed/lmz030] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
51 Foster GG, Grant MJ, Thomas SM, Cameron B, Raiff D, Corbet K, Loitsch G, Ferreri C, Horwitz M. Treatment with Foscarnet after Allogeneic Hematopoietic Cell Transplant (Allo-HCT) Is Associated with Long-Term Loss of Renal Function. Biol Blood Marrow Transplant 2020;26:1597-606. [PMID: 32450288 DOI: 10.1016/j.bbmt.2020.05.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
52 Peffault De Latour R, Chevallier P, Blaise D, Alami S, Lévy-Bachelot L, Allavoine T, Tadmouri A, Blomkvist J, Duhamel A, Srour M, Beauvais D, Yakoub-Agha I. Clinical and economic impact of treated CMV infection in adult CMV-seropositive patients after allogeneic hematopoietic cell transplantation. J Med Virol 2020. [PMID: 32297984 DOI: 10.1002/jmv.25895] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
53 Al Talhi YM, Hariri B, Alsulaimani F, Almadani M, Abbas A, AlDabbagh M. Cytomegalovirus viremia among pediatric oncology non-stem cell transplant patients with prolonged fever neutropenia. J Infect Public Health 2020;13:1176-80. [PMID: 32224110 DOI: 10.1016/j.jiph.2020.02.001] [Reference Citation Analysis]
54 Styczyński J. Prophylaxis vs preemptive therapy in prevention of CMV infection: new insight on prophylactic strategy after allogeneic hematopoietic cell transplantation. Acta Haematologica Polonica 2020;51:17-23. [DOI: 10.2478/ahp-2020-0005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
55 Camargo JF. Cytomegalovirus in Hematopoietic Stem Cell Transplant Recipients: Prevention, Diagnosis, and Treatment. Emerging Transplant Infections 2020. [DOI: 10.1007/978-3-030-01751-4_25-1] [Reference Citation Analysis]
56 Ishay Y, Ilan Y. Hepatitis A and Other Viral Infections. Liver Immunology 2020. [DOI: 10.1007/978-3-030-51709-0_15] [Reference Citation Analysis]
57 Czyzewski K, Dziedzic M, Salamonowicz M, Fraczkiewicz J, Zajac-Spychala O, Zaucha-Prazmo A, Gozdzik J, Galazka P, Bartoszewicz N, Demidowicz E, Styczynski J. Epidemiology, Outcome and Risk Factors Analysis of Viral Infections in Children and Adolescents Undergoing Hematopoietic Cell Transplantation: Antiviral Drugs Do Not Prevent Epstein-Barr Virus Reactivation. Infect Drug Resist 2019;12:3893-902. [PMID: 31908501 DOI: 10.2147/IDR.S224291] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
58 Cona A, Tesoro D, Chiamenti M, Merlini E, Ferrari D, Marti A, Codecà C, Ancona G, Tincati C, d'Arminio Monforte A, Marchetti G. Disseminated cytomegalovirus disease after bendamustine: a case report and analysis of circulating B- and T-cell subsets. BMC Infect Dis 2019;19:881. [PMID: 31640581 DOI: 10.1186/s12879-019-4545-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
59 Poh KC, Zheng S. A rare case of CMV pneumonia in HIV-infection. Respir Med Case Rep 2019;28:100945. [PMID: 31709138 DOI: 10.1016/j.rmcr.2019.100945] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
60 Styczyński J. ABC of viral infections in hematology: focus on herpesviruses. Acta Haematologica Polonica 2019;50:159-66. [DOI: 10.2478/ahp-2019-0026] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
61 Malagola M, Greco R, Santarone S, Natale A, Iori AP, Quatrocchi L, Barbieri W, Bruzzese A, Leotta S, Carotti A, Pierini A, Bernardi S, Morello E, Polverelli N, Turra A, Cattina F, Gandolfi L, Rambaldi B, Lorentino F, Serio F, Milone G, Velardi A, Foà R, Ciceri F, Russo D, Peccatori J. CMV Management with Specific Immunoglobulins: A Multicentric Retrospective Analysis on 92 Allotransplanted Patients. Mediterr J Hematol Infect Dis 2019;11:e2019048. [PMID: 31528314 DOI: 10.4084/MJHID.2019.048] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
62 Pande A, Dubberke ER. Cytomegalovirus Infections of the Stem Cell Transplant Recipient and Hematologic Malignancy Patient. Infectious Disease Clinics of North America 2019;33:485-500. [DOI: 10.1016/j.idc.2019.02.008] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
63 Cho SY, Lee DG, Kim HJ. Cytomegalovirus Infections after Hematopoietic Stem Cell Transplantation: Current Status and Future Immunotherapy. Int J Mol Sci 2019;20:E2666. [PMID: 31151230 DOI: 10.3390/ijms20112666] [Cited by in Crossref: 36] [Cited by in F6Publishing: 46] [Article Influence: 12.0] [Reference Citation Analysis]
64 Restrepo-Gualteros SM, Gutierrez MJ, Villamil-Osorio M, Arroyo MA, Nino G. Challenges and Clinical Implications of the Diagnosis of Cytomegalovirus Lung Infection in Children. Curr Infect Dis Rep 2019;21:24. [PMID: 31147863 DOI: 10.1007/s11908-019-0681-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
65 Zhang S, Caldeira-Dantas S, Smith CJ, Snyder CM. Persistent viral replication and the development of T-cell responses after intranasal infection by MCMV. Med Microbiol Immunol 2019;208:457-68. [PMID: 30848361 DOI: 10.1007/s00430-019-00589-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
66 Campos CF, Leite L, Pereira P, Vaz CP, Branca R, Campilho F, Freitas F, Ligeiro D, Marques A, Torrado E, Silvestre R, Lacerda JF, Campos A Jr, Cunha C, Carvalho A. PTX3 Polymorphisms Influence Cytomegalovirus Reactivation After Stem-Cell Transplantation. Front Immunol 2019;10:88. [PMID: 30766534 DOI: 10.3389/fimmu.2019.00088] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
67 Willis EL, Stevens TL, White GL, Mcfarlane D. Characterization of Baboon Cytomegalovirus Infection in Healthy Adult Baboons (Papio anubis). Comp Med 2019;69:55-62. [PMID: 30704552 DOI: 10.30802/AALAS-CM-18-000050] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
68 Zhang R, Zhang Y, Hu J, Wu W, Chen X, Lu Z, Yang R, Huang Y, Fan J. Specific T-cell receptor gene transfer enhances immune response: A potential therapeutic strategy for the control of human cytomegalovirus infection in immunocompromised patients. Cell Immunol 2019;336:58-65. [PMID: 30626494 DOI: 10.1016/j.cellimm.2018.12.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
69 Majewska A, Młynarczyk-bonikowska B, Malejczyk M, Majewski S, Młynarczyk G. Possibilities Of Prevention And Treatment Of Human Cytomegalovirus Infections Including New Drugs And Compounds With Potential Application. Postępy Mikrobiologii - Advancements of Microbiology 2019;58:291-299. [DOI: 10.21307/pm-2019.58.3.291] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
70 Yeo SJ, Kwon KT, Kim ES, Jung MK, Kim SK, Lee HS, Lee JS, Lee SW, Lee YJ, Kwak SG, Han S. Development of a Predictive Model Using Endoscopic Features for Gastric Cytomegalovirus Infection in Renal Transplant Patients. Transplantation 2019;103:998-1004. [PMID: 30507742 DOI: 10.1097/TP.0000000000002554] [Reference Citation Analysis]
71 Cao K, Marin D, Sekine T, Rondon G, Zhao W, Smith NT, Daher M, Wang Q, Li L, Saliba RM, Pingali R, Popat U, Hosing C, Olson A, Oran B, Basar R, Mehta RS, Champlin R, Shpall EJ, Rezvani K. Donor NKG2C Copy Number: An Independent Predictor for CMV Reactivation After Double Cord Blood Transplantation. Front Immunol 2018;9:2444. [PMID: 30405633 DOI: 10.3389/fimmu.2018.02444] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
72 Melendez-Munoz R, Marchalik R, Jerussi T, Dimitrova D, Nussenblatt V, Beri A, Rai K, Wilder JS, Barrett AJ, Battiwalla M, Childs RW, Fitzhugh CD, Fowler DH, Fry TJ, Gress RE, Hsieh MM, Ito S, Kang EM, Pavletic SZ, Shah NN, Tisdale JF, Gea-Banacloche J, Kanakry CG, Kanakry JA. Cytomegalovirus Infection Incidence and Risk Factors Across Diverse Hematopoietic Cell Transplantation Platforms Using a Standardized Monitoring and Treatment Approach: A Comprehensive Evaluation from a Single Institution. Biol Blood Marrow Transplant 2019;25:577-86. [PMID: 30342913 DOI: 10.1016/j.bbmt.2018.10.011] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 6.5] [Reference Citation Analysis]
73 Frerichs KA, Bosman PWC, Nijhof IS, Zweegman S, van de Donk NWCJ. Cytomegalovirus Reactivation in a Patient With Extensively Pretreated Multiple Myeloma During Daratumumab Treatment. Clin Lymphoma Myeloma Leuk 2019;19:e9-e11. [PMID: 30392824 DOI: 10.1016/j.clml.2018.10.002] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 3.5] [Reference Citation Analysis]
74 Roche KL, Nukui M, Krishna BA, O'Connor CM, Murphy EA. Selective 4-Thiouracil Labeling of RNA Transcripts within Latently Infected Cells after Infection with Human Cytomegalovirus Expressing Functional Uracil Phosphoribosyltransferase. J Virol 2018;92:e00880-18. [PMID: 30089702 DOI: 10.1128/JVI.00880-18] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
75 Collins-McMillen D, Buehler J, Peppenelli M, Goodrum F. Molecular Determinants and the Regulation of Human Cytomegalovirus Latency and Reactivation. Viruses. 2018;10. [PMID: 30127257 DOI: 10.3390/v10080444] [Cited by in Crossref: 78] [Cited by in F6Publishing: 79] [Article Influence: 19.5] [Reference Citation Analysis]
76 Dandachi D, Rodriguez-Barradas MC. Viral pneumonia: etiologies and treatment. J Investig Med. 2018;66:957-965. [PMID: 29680828 DOI: 10.1136/jim-2018-000712] [Cited by in Crossref: 47] [Cited by in F6Publishing: 50] [Article Influence: 11.8] [Reference Citation Analysis]